PROFIL PENGGUNAAN OBAT ANTIVIRUS COVID-19 DI RSUD dr. MURJANI-SAMPIT

  • Etik Suryanti Universitas Surabaya
  • Abdul Rahem Fakultas Farmasi Universitas Airlangga Surabaya
  • Anita Purnamayanti Fakultas Farmasi Universitas Surabaya
Keywords: covid-19, antiviral, percentage

Abstract

Coronavirus Disease 2019 (Covid-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2). The World Health Organization (WHO) until now still defines Covid-19 as a global pandemic where this pandemic is the cause of the biggest public health crisis in this century. RSUD dr. Murjani-Sampit uses several antivirals, including Oseltamivir 75 mg, Favipiravir 200 mg, Remdesivir 200 mg. The purpose of this study was to determine the antiviral profile given to covid-19 patients at dr. Murjani-Sampit.

This study used a total sample of hospitalized patients who were given COVID-19 antiviral therapy in the period August 2021. This research method used an observational research design with retrospective sampling. Data collection techniques based on observation of patient prescription data recorded in the pharmacy installation management information system of RSUD dr. Murjani-Sampit. The analytical method used is descriptive analysis with the most data on the use of antiviral drugs and the average percentage for the period August 2021 at dr. Murjani-Sampit which opened 275 patients.

The results showed that the most widely administered antivirals were favipiravir 200 mg in 249 patients (90.54%), remdesivir 200 mg in 17 patients (6.18%) and oseltamivir as adjuvant or additional therapy due to influenza in 9 patients (3.27%). The conclusion of this study is that the antivirals used include oseltamivir 75 mg 3.27%, favipiravir 200 mg 90.54%, and remdesivir 200 mg 6.18%.

References

World Health Organization. WHO announces COVID-19 outbreak a pandemic. Accessed April 14, 2020.

Jean-Philippe Adam, Michael Khazaka, Fouad Charikhi, Maggee Clervil, Denis Daniel Huot, Joseph Jebailey, Pascal O, Jean Morin, Marie-Claude Langevin, Management of human resources of a pharmacy department during the COVID-19 pandemic:

Keputusan Menteri Kesehatan Republik Indonesia Nomor Hk.01.07/Menkes/5671/2021 tentang Manajemen Klinis Tata Laksana Corona Virus Disease 2019 (Covid-19) di Fasilitas Pelayanan Kesehatan.;2021.

Https://mmc.kalteng.go.id/berita/read/35308/kasus-harian-covid-19-15-agustus-2021-sembuh-361-orang-konfirmasi-482-orang-mari-terus-disiplin-prokes

Satuan Tugas Pencegahan dan Pengendalian Covid-19. 2021. Peta Sebaran Covid-19 per Provinsi di Indonesia. Tersedia di https://covid19.go.id/

Portal Pemerintah Provinsi Kalimantan Tengah. 2021. Kasus Harian Covid-19 di Provinsi Kalimantan Tengah bulan Juli – Agustus 2021. Tersedia di https://kalteng.go.id/

Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020;395:1137-44.

World Health Organization. COVID-19 Weekly Epidemiological Update Edition 56, 7 September 2021. World Heal Organ COVID-19 Wkly Epidermiological Updat. 2021;(49):1-3.

Tan Q, Duan L, Ma Y, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Elsevier. 2020;(2 September 2020).

United States Food and Drug Administration, FDA First Approves First Treatment for Covid-19. FDA News Release Oct 22, 2020.

European Medicine Agency. First Covid-19 treatment recommended for EU authorization. Press release June 25, 2020

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383(19):1813-1826.

Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020;6(10):1192-1198.

Fujifilm Toyama Chemical. Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients. FUJIFILM Toyama Chemical Co., Ltd. Published 2020. Accessed September 23, 2020. https://www.fujifilm.com/jp/en/news/hq/5451

Burhan E, Dwi Susanto A, Isbaniah F, et al. Pedoman Tatalaksana Covid-19 Edisi 3. Pulungan, Hik NDP, TIM, eds.); 2020.

Informatorium Obat Covid-19 di Indonesia, Badan Pengawas Obat dan Makanan Republik Indonesia ISBN 978-602-415-069-3 Edisi 3 Cetakan Pertama September 2021

Published
2022-03-29
How to Cite
Suryanti, E., Rahem, A., & Purnamayanti, A. (2022). PROFIL PENGGUNAAN OBAT ANTIVIRUS COVID-19 DI RSUD dr. MURJANI-SAMPIT. Jurnal Ilmiah Ibnu Sina, 7(1), 116-123. https://doi.org/10.36387/jiis.v7i1.842
Section
Artikel

Most read articles by the same author(s)